NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+3%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.85B
AUM Growth
+$1.85B
(+28%)
Cap. Flow
+$427M
Cap. Flow
% of AUM
23.03%
Top 10 Holdings %
Top 10 Hldgs %
65.27%
Holding
41
New
6
Increased
10
Reduced
6
Closed
3
Top Buys
| 1 |
Vanguard Total Stock Market ETF
VTI
|
$278M |
| 2 |
TEM
Tempus AI, Inc. Class A Common Stock
TEM
|
$143M |
| 3 |
Edgewise Therapeutics
EWTX
|
$114M |
| 4 |
Merus
MRUS
|
$39.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$31.5M |
Top Sells
| 1 |
Edgewell Personal Care
EPC
|
$116M |
| 2 |
ASML
ASML
|
$50.3M |
| 3 |
Insmed
INSM
|
$36.1M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$19.8M |
| 5 |
Inspire Medical Systems
INSP
|
$14.1M |
Sector Composition
| 1 | Healthcare | 53.05% |
| 2 | Technology | 16.21% |
| 3 | Financials | 9.98% |
| 4 | Communication Services | 2.26% |
| 5 | Consumer Discretionary | 1.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vanguard Total Stock Market ETF
VTI
$526B
| $278M | 14.98% | +1,038,550 | New | +$278M |
|
2
Brookfield
BN
$98.3B
| $161M | 8.69% | 3,880,230 | – | – |
|
|
TEM
3
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $143M | 7.69% | +4,074,419 | New | +$143M |
|
|
4
ASML
ASML
$292B
| $136M | 7.35% | 133,336 -49,200 | -27% | -$50.3M |
|
5
Salesforce
CRM
$245B
| $123M | 6.66% | 480,160 | – | – |
|
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $114M | 6.16% | +6,344,430 | New | +$114M |
|
7
Corcept Therapeutics
CORT
$7.35B
| $78.3M | 4.22% | 2,411,362 | – | – |
|
8
Vaxcyte
PCVX
$4B
| $71.7M | 3.87% | 950,000 +105,000 | +12% | +$7.93M |
|
|
9
Insmed
INSM
$28.8B
| $53.6M | 2.89% | 800,000 -539,304 | -40% | -$36.1M |
|
10
Mirum Pharmaceuticals
MIRM
$3.71B
| $51.3M | 2.76% | 1,500,000 | – | – |
|
11
Crinetics Pharmaceuticals
CRNX
$2.92B
| $44.8M | 2.41% | 1,000,000 -98,600 | -9% | -$4.42M |
|
12
Cable One
CABO
$909M
| $41.9M | 2.26% | 118,403 | – | – |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $40.3M | 2.17% | 490,000 +40,000 | +9% | +$3.29M |
|
|
14
Merus
MRUS
$4.98B
| $39.9M | 2.15% | +675,000 | New | +$39.9M |
|
15
Apple
AAPL
$3.45T
| $38.5M | 2.08% | 182,960 | – | – |
|
16
Alibaba
BABA
$322B
| $36.1M | 1.94% | 500,827 | – | – |
|
17
Pharvaris
PHVS
$1.39B
| $32.4M | 1.75% | 1,725,000 +556,970 | +48% | +$10.5M |
|
|
18
Celldex Therapeutics
CLDX
$1.47B
| $31.5M | 1.7% | +850,000 | New | +$31.5M |
|
19
4D Molecular Therapeutics
FDMT
$288M
| $29.4M | 1.58% | 1,400,000 | – | – |
|
20
LanzaTech
LNZA
$49.1M
| $29.3M | 1.58% | 15,814,845 | – | – |
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $28.8M | 1.55% | 118,383 | – | – |
|
22
ArriVent BioPharma
AVBP
$776M
| $27.8M | 1.5% | 1,500,000 +422,860 | +39% | +$7.84M |
|
23
Viridian Therapeutics
VRDN
$1.5B
| $26M | 1.4% | 2,000,000 +900,000 | +82% | +$11.7M |
|
|
CRGX
24
DELISTED
CARGO Therapeutics
CRGX
| $25.4M | 1.37% | 1,544,000 +294,000 | +24% | +$4.83M |
|
25
Amicus Therapeutics
FOLD
$2.34B
| $24.8M | 1.34% | 2,500,000 | – | – |
|